title: The effect of RU486 on the gene expression profile in an endometrial explant model.
abstract: Administration of RU486 in vivo during the receptive phase rapidly renders the endometrium non-receptive to the implanting embryo. In order to identify key pathways responsible for endometrial receptivity we have used cDNA arrays to monitor gene expression changes in short-term endometrial explants in response to RU486. Endometrial biopsies from five normal fertile women at mid-secretory phase were cultured in the presence of estradiol and progesterone with or without RU486 for 12 h. cDNA arrays were produced containing approximately 1000 sequence-verified clones which included genes known to be important in angiogenesis, apoptosis, cell signalling, extracellular matrix remodelling and cell cycle regulation. cDNA probes from the paired endometrial samples were hybridized to the arrays and hybridization signals were quantified. A total of 12 genes displayed significant changes in expression; six were up-regulated and six down-regulated following RU486 treatment. For five of these genes this is the first report suggesting that they are regulated by steroids in the endometrium. JAK1 and JNK1 were two of the genes shown by the arrays to be down-regulated in RU486-treated endometrial explants. This was confirmed by real time RT-PCR. JAK1 immunoreactivity was localized to both glandular epithelium and the stroma of normal endometrium and staining was much stronger in the luteal phase of the cycle. These results show that components of two important signalling pathways in endometrium-the JAK/STAT pathway, and the JNK pathway-are altered by RU486. Genes whose expression is controlled by these pathways are likely to be involved in the mechanism by which steroids render the endometrium receptive to the implanting embryo.
authors.affiliation: Reproductive Molecular Research Group, Department of Pathology, University of Cambridge, Cambridge, UK. rc296@cam.ac.uk
authors.forename: R D
authors.initials: RD
authors.lastname: Catalano
authors.forename: A
authors.initials: A
authors.lastname: Yanaihara
authors.forename: A L
authors.initials: AL
authors.lastname: Evans
authors.forename: D
authors.initials: D
authors.lastname: Rocha
authors.forename: A
authors.initials: A
authors.lastname: Prentice
authors.forename: S
authors.initials: S
authors.lastname: Saidi
authors.forename: C G
authors.initials: CG
authors.lastname: Print
authors.forename: D S
authors.initials: DS
authors.lastname: Charnock-Jones
authors.forename: A M
authors.initials: AM
authors.lastname: Sharkey
authors.forename: S K
authors.initials: SK
authors.lastname: Smith
mesh_terms: D000328:Adult; D046508:Culture Techniques; D004717:Endometrium / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D005260:Female; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D053613:Janus Kinase 1; D008186:Luteolytic Agents / Q000494:pharmacology*; D008597:Menstrual Cycle; D015735:Mifepristone / Q000494:pharmacology*; D020411:Oligonucleotide Array Sequence Analysis; D011505:Protein-Tyrosine Kinases / Q000235:genetics / Q000378:metabolism
chemical_list: D008186:Luteolytic Agents; D015735:Mifepristone; D011505:Protein-Tyrosine Kinases; C507904:JAK1 protein, human; D053613:Janus Kinase 1